# X4P-001 and Pembrolizumab in Patients With Advanced Melanoma

Source: https://onco.cc/trials/nct02823405/  
OnCo record `nct02823405` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Mavorixafor and Pembrolizumab in Melanoma, run by X4 Pharmaceuticals, completed.

## Summary

X4P-001 and Pembrolizumab in Patients With Advanced Melanoma is a phase 1 interventional study registered as NCT02823405 by X4 Pharmaceuticals, with 16 participants recorded, started 2016-09-15 and reaching its primary completion in 2018-03-15. Interventions recorded: X4P-001, Pembrolizumab. Conditions recorded: Melanoma.

Linked to the drug Mavorixafor because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02823405
- Phase: 1
- Setting: A Phase 1b Trial of X4P-001 Alone and With Pembrolizumab in Patients With Advanced Melanoma
- Sponsor: X4 Pharmaceuticals
- Enrolled: 16

## Sources

- ClinicalTrials.gov NCT02823405: https://clinicaltrials.gov/study/NCT02823405

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Mavorixafor](https://onco.cc/drugs/mavorixafor/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [X4 Pharmaceuticals](https://onco.cc/companies/x4-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct02823405.json